Announced Sat, 30 May · 12:44 IST

Subscription to the Right Issue of equity shares of its Wholly Owned Subsidiary, Acume Chemicals Private Limited

Fund Raising View source PDF

ACI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.5%1-day move
₹522.00
prior close
₹525.25
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.0-0.5-0.6+2.5+2.5+1.7-1.1-2.0+2.5+2.5-0.9
Up moveDown movePending
AI summary

Archean Chemical Industries Limited will invest up to Rs. 170 crore in its wholly owned subsidiary, Acume Chemicals Private Limited, by subscribing to the subsidiary's rights issue at face value of Rs. 10 per share. The investment will be made in one or more tranches within one month. Acume Chemicals is in the Bromine Derivatives business, with revenue growing from Rs. 51.44 lakhs in FY23 to Rs. 8,111.53 lakhs in FY25. The company currently holds 100% equity and will maintain 100% ownership after the rights issue. The stated purposes include strengthening the subsidiary's capital base, supporting business expansion, improving capacity utilization, and reducing external borrowings. This is a related party transaction undertaken on an arm's length basis via rights.

Likely market impact

This investment strengthens the subsidiary's balance sheet and reduces its debt burden, which could benefit the parent company's consolidated financials. Since Archean maintains 100% ownership, existing shareholders do not face dilution, but the Rs. 170 crore outflow may limit funds available for other purposes.